These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 2452774

  • 21. Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma.
    Mann WJ, Patsner B, Cohen H, Loesch M.
    J Natl Cancer Inst; 1988 Apr 06; 80(3):208-9. PubMed ID: 3162284
    [Abstract] [Full Text] [Related]

  • 22. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
    Yue K, Bian M, Zhu D, Liu W, Siu S.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr 06; 17(2):128-32. PubMed ID: 7656393
    [Abstract] [Full Text] [Related]

  • 23. Predictive value of CA-125 levels in advanced ovarian cancer.
    Patsner B, Day TG.
    Am J Obstet Gynecol; 1987 Feb 06; 156(2):440-1. PubMed ID: 3469916
    [Abstract] [Full Text] [Related]

  • 24. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ, Yu YH, Daly L, DeSombre K, Anselmino L, Hass GM, Berchuck A, Soper JT, Clarke-Pearson DL, Boyer C.
    J Clin Oncol; 1993 Aug 06; 11(8):1506-10. PubMed ID: 8336189
    [Abstract] [Full Text] [Related]

  • 25. Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence.
    Schilthuis MS, Aalders JG, Bouma J, Kooi H, Fleuren GJ, Willemse PH, De Bruijn HW.
    Br J Obstet Gynaecol; 1987 Mar 06; 94(3):202-7. PubMed ID: 3471274
    [Abstract] [Full Text] [Related]

  • 26. Serum alpha 1-acid glycoprotein in epithelial ovarian cancer.
    Piver MS, Moyer M, Diakun K, Lele SB, Chu TM.
    Gynecol Oncol; 1988 Mar 06; 29(3):305-8. PubMed ID: 3345951
    [Abstract] [Full Text] [Related]

  • 27. Tumor markers in epithelial ovarian cancer. Clinical applications.
    Hempling RE.
    Obstet Gynecol Clin North Am; 1994 Mar 06; 21(1):41-61. PubMed ID: 8015766
    [Abstract] [Full Text] [Related]

  • 28. Biochemical markers in ovarian cancer.
    Kiricuta I, Bojan O, Munteanu S.
    Arch Geschwulstforsch; 1986 Mar 06; 56(1):35-8. PubMed ID: 3964031
    [Abstract] [Full Text] [Related]

  • 29. The evaluation of putative tumor markers for malignant melanoma.
    Reintgen DS, Cruse CW, Wells KE, Saba HI, Fabri PJ.
    Ann Plast Surg; 1992 Jan 06; 28(1):55-9. PubMed ID: 1642407
    [Abstract] [Full Text] [Related]

  • 30. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
    Cane P, Azen C, Lopez E, Platt LD, Karlan BY.
    Gynecol Oncol; 1995 May 06; 57(2):240-5. PubMed ID: 7729742
    [Abstract] [Full Text] [Related]

  • 31. Breast cancer and family history: levels of lipid-associated sialic acid in plasma and absent family history of breast cancer in women who have breast tumors.
    Brower ST, Tartter P, Weiss S, Luderer AA, Lehrer S.
    Mt Sinai J Med; 1995 Nov 06; 62(6):419-21. PubMed ID: 8692154
    [Abstract] [Full Text] [Related]

  • 32. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
    Meden H, Rath W, Teichmann A, Kuhn W.
    Onkologie; 1989 Oct 06; 12(5):217-20. PubMed ID: 2685687
    [Abstract] [Full Text] [Related]

  • 33. Predictive value of serial CA 125 antigen levels in ovarian cancer evaluated by second-look laparotomy.
    Khoo SK, Hurst T, Webb MJ, Dickie GJ, Kearsley JH, Mackay EV.
    Eur J Cancer Clin Oncol; 1987 Jun 06; 23(6):765-71. PubMed ID: 3477461
    [Abstract] [Full Text] [Related]

  • 34. CA 125 surveillance and second-look laparotomy in ovarian carcinoma.
    Atack DB, Nisker JA, Allen HH, Tustanoff ER, Levin L.
    Am J Obstet Gynecol; 1986 Feb 06; 154(2):287-9. PubMed ID: 3456202
    [Abstract] [Full Text] [Related]

  • 35. Serum CA 125 in epithelial ovarian cancer. A longitudinal study.
    Brioschi PA, Irion O, Bischof P, Bader M, Forni M, Krauer F.
    Br J Obstet Gynaecol; 1987 Mar 06; 94(3):196-201. PubMed ID: 3471273
    [Abstract] [Full Text] [Related]

  • 36. Management of patients with gynecologic cancer by serum sialic acid determination.
    Shimizu Y, Hasumi K, Masubuchi K, Okudaira Y.
    Gynecol Oncol; 1989 May 06; 33(2):231-6. PubMed ID: 2703183
    [Abstract] [Full Text] [Related]

  • 37. The lack of utility of a tumor marker panel in head and neck carcinoma. Squamous cell carcinoma antigen, carcinoembryonic antigen, lipid-associated sialic acid, and CA-125.
    Straka MB, Wagner RL, Johnson JT, Kachman KK, Eibling DE.
    Arch Otolaryngol Head Neck Surg; 1992 Aug 06; 118(8):802-5. PubMed ID: 1642830
    [Abstract] [Full Text] [Related]

  • 38. Elevated serum and urine sialic acid levels in renal diseases.
    Ozben T.
    Ann Clin Biochem; 1991 Jan 06; 28 ( Pt 1)():44-8. PubMed ID: 2024933
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.
    McGuckin MA, Layton GT, Bailey MJ, Hurst T, Khoo SK, Ward BG.
    Gynecol Oncol; 1990 May 06; 37(2):165-71. PubMed ID: 1693126
    [Abstract] [Full Text] [Related]

  • 40. Usefulness and potential pitfalls of sialic acid determination in sera of patients with ovarian tumors.
    Berra B, Rapelli S, Monticelli G, Fighetti MA, Della Mea I, Raspagliesi F, Di Re E, Ringhini R, Bombardieri E.
    Int J Biol Markers; 1986 May 06; 1(1):39-46. PubMed ID: 3693972
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.